Lördag 25 Oktober | 15:50:42 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-03-31 08:00 Bokslutskommuniké 2025
2025-11-05 N/A Extra Bolagsstämma 2025
2025-08-29 - Kvartalsrapport 2025-Q2
2025-07-01 - X-dag ordinarie utdelning MAGNA 0.00 SEK
2025-06-30 - Årsstämma
2025-03-05 - Bokslutskommuniké 2024
2024-11-15 - 15-10 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-07-01 - X-dag ordinarie utdelning MAGNA 0.00 SEK
2024-06-28 - Årsstämma
2024-04-26 - Extra Bolagsstämma 2024
2024-03-29 - Bokslutskommuniké 2023
2023-11-24 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-06-22 - Årsstämma
2023-06-01 - Kvartalsrapport 2023-Q1
2023-05-16 - X-dag ordinarie utdelning MAGNA 0.00 SEK
2023-03-31 - Bokslutskommuniké 2022
2023-01-20 - Extra Bolagsstämma 2022
2022-11-23 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-06-21 - X-dag ordinarie utdelning MAGNA 0.00 SEK
2022-06-20 - Årsstämma
2022-05-25 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-11-23 - Kvartalsrapport 2021-Q3
2021-08-24 - Kvartalsrapport 2021-Q2
2021-06-29 - X-dag ordinarie utdelning MAGNA 0.00 SEK
2021-06-28 - Årsstämma
2021-05-25 - Kvartalsrapport 2021-Q1
2021-03-09 - Extra Bolagsstämma 2021
2021-02-26 - Bokslutskommuniké 2020
2020-11-27 - Kvartalsrapport 2020-Q3
2020-08-27 - Kvartalsrapport 2020-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Magnasense är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom forskning och utveckling av olika läkemedelskandidater. Produktportföljen är bred och inkluderar huvudsakligen läkemedel för behandling av multipel skleros. Utöver huvudverksamheten erbjuds tillhörande kringtjänster. Verksamheten drivs i samarbete med övriga läkemedelsaktörer, där störst närvaro återfinns inom Norden.
2025-10-21 21:05:00

Magnasense AB (“Magnasense” or the “Company”) announces that the Swedish Securities Council today has granted an exemption from the mandatory bid obligation for Subgen AI Foundation in connection with Magnasense’s conditional reverse takeover of Subgen AI Limited, corporate registration number 15374966 (“Subgen” and the “Transaction”).

On 22 July 2025, Magnasense entered into a conditional agreement regarding a reverse takeover of Subgen. The shareholder Subgen AI Foundation will as the largest shareholder in Subgen, through the Transaction, receive approximately 38.9 percent of the capital and 72.0 percent of the votes in the Company, which gives rise to a mandatory bid obligation in accordance with the takeover rules for certain trading platforms. Subgen AI Foundation has hence applied for, and today received, exemption from the mandatory bid obligation from the Swedish Securities Council (AMN 2025:48).

The exemption from the mandatory bid obligation is conditional upon the shareholders of the Company being informed of the maximum capital and voting rights that Subgen AI Foundation may obtain, prior to the extraordinary general meeting to be held on 5 November 2025. The exemption is further conditional upon the shareholders of Magnasense being informed, prior to the extraordinary general meeting to be held on 5 November 2025 to decide on the Transaction, of the capital and voting rights that Subgen AI Foundation, and any other related natural or legal persons may obtain by subscribing for the shares in question. This information was included in the notice to the extraordinary general meeting published on 3 October 2025. Furthermore, the exemption is conditional upon that the resolution on the Transaction is supported by shareholders representing at least two-thirds of both the votes cast and the shares represented at the meeting, whereby shares held by Subgen AI Foundation and related natural or legal persons shall be disregarded in the vote count

The completion of the Transaction is subject to the Transaction (and certain related resolutions) being approved at the extraordinary general meeting in the Company to be held on 5 November 2025.